Skip to main content
. 2013 Oct 27;93(1):71–80. doi: 10.1007/s00277-013-1937-4

Fig. 1.

Fig. 1

Overview of evaluable patients according to age groups. n Number of patients, CML chronic myeloid leukemia, CP chronic phase, OS overall survival, CCR complete cytogenetic remission, MMR major molecular remission, MR 4 molecular remission ≤0.01 % on the international scale